This is a Study to Verify if Periarticular Hip Injection of Corticosteroid After Hip Replacement Reduce the Pain and the Hospitalisation Time

Launched by ENTE OSPEDALIERO CANTONALE, BELLINZONA · Aug 24, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating whether injecting a corticosteroid (a type of medication that reduces inflammation) around the hip joint during hip replacement surgery can help patients feel less pain after the operation and shorten their hospital stay. The researchers want to find out if this treatment can also reduce the need for pain relief medications and lower overall hospital costs for patients recovering from femoral neck fractures, which are breaks in the upper part of the thigh bone.

To take part in this study, participants need to be between 50 and 90 years old and scheduled for a specific type of hip replacement surgery. They should have a body mass index (BMI) between 18.5 and 35 and be able to understand and follow the study's instructions. However, some individuals may not be eligible, including those who have certain medical conditions or are currently on specific medications. If you qualify, you can expect to receive close monitoring during your recovery to see how well the injection works in reducing pain and improving your hospital experience.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing unilateral cemented hip endoprosthesis for femoral neck fracture
• • Patients aged 50-90 years old
• • Patients with a BMI \>18.5 and \<35
• • Patients able to provide informed consent and follow all the study procedures as indicated by the protocol
• • Informed Consent as documented by signature
• Exclusion Criteria:
• • Contraindications to steroids
• • Revision endoprosthesis
• • Active steroid or immunosuppressive therapy in the last 30 days before the operation
• • Pregnant or breast-feeding women
• • Presence of other clinically significant concomitant disease states (ASA IV)
• • Uncontrolled diabetes mellitus
• • Contraindications to NSAIDs
• • Chronic systemic diseases as immunodeficiency, autoimmune disease (Systemic Lupus Erythematosus, SLE), gout, rheumatic arthritis
• • Known or suspected non-compliance, drug or alcohol abuse
• • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
• • Participation in another study with investigational drug within the 30 days preceding and during the present study
• • Previous enrolment into the current study
• • Enrolment of the investigator, his/her family members, employees and other dependent persons.